Back to Search
Start Over
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
- Publication Year :
- 2017
-
Abstract
- Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell percentage was not or just mildly affected and was slightly below the lowest normal limit already before alemtuzumab. These cases anticipate further studies aimed to investigate whether the evaluation of the CD4+ cell percentage could represent a helpful tool to address the individual clinical response to alemtuzumab.
- Subjects :
- 0301 basic medicine
Adult
CD4-Positive T-Lymphocytes
medicine.medical_specialty
Neurology
Multiple Sclerosis
Population
Immunology
Antineoplastic Agents
Treatment response
03 medical and health sciences
CD4 + lymphocytes
Antineoplastic Agents, Immunological
0302 clinical medicine
medicine
Effective treatment
Humans
Immunology and Allergy
education
Alemtuzumab
Immune reconstitution
Multiple sclerosis
Female
Neurology (clinical)
education.field_of_study
Cd4 t cell
business.industry
medicine.disease
Normal limit
Persistent Disease
030104 developmental biology
Immunological
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....e1bc9ae83376513587b59b4db3cca982